New COPD drug given marketing authorisation
The European Commission has licensed umeclidinium (Incruse) as a once-daily, maintenance bronchodilator treatment to relieve the symptoms of chronic obstructive pulmonary disease.
Get unlimited access
As a subscriber you will benefit from:
- Full online and mobile access to news and opinion stories
Customised email alerts straight to your inbox (over 30 alerts available)
- 4,500 practice articles in our archive
- Over £500 worth of CPD learning units